Bacteriophages for Gut Health

(Phage-CLEAR Trial)

This trial aims to test the effectiveness of two bacteriophage treatments, MuniPhage and RenuPhage, in improving gut and skin health. Bacteriophages are tiny viruses that attack specific bacteria in the body. The trial targets certain strains of E. coli and Staphylococcus aureus that may cause digestive issues and skin problems. It suits individuals aged 18 to 75 who frequently experience mild to moderate digestive troubles, such as bloating, constipation, or diarrhea. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on innovative treatments for common health issues.

Research has shown that bacteriophages, such as those in MuniPhage and RenuPhage, are generally safe for people. One study found that these phages are well-tolerated and target harmful bacteria in the gut, promoting the growth of beneficial bacteria. Another study noted that some patients using phage therapy experienced side effects, but most were not serious.

For RenuPhage, research suggests that a mix of four bacteriophages is safe and tolerable. These phages specifically attack certain harmful bacteria, leaving human cells and beneficial bacteria unharmed. This reduces the risk of side effects like drug toxicity, which can occur with some medications.

Unlike the standard treatments for gut-related issues, which often involve antibiotics or probiotics, MuniPhage and RenuPhage utilize bacteriophages, which are viruses that specifically target and destroy harmful bacteria. MuniPhage is designed to target specific pro-inflammatory E. coli strains, while RenuPhage focuses on reducing Staphylococcus aureus in the gut and potentially on the skin. This targeted approach offers a precision that antibiotics lack, potentially minimizing side effects and preserving beneficial bacteria. Researchers are excited because these treatments promise a novel mechanism of action that could revolutionize gut health management by directly targeting harmful bacteria without disturbing the overall microbiome balance.

Research has shown that bacteriophages, like those in MuniPhage, can restore gut balance by targeting harmful bacteria, such as certain types of E. coli. Studies have found that these phages reduce inflammation and improve gut health by specifically targeting and reducing harmful bacteria. In this trial, participants may receive MuniPhage, designed for this purpose.